Xeljanz Safety Profile & Adverse Events

Safety Profile Overview

First oral JAK inhibitor approved. Post-marketing study revealed increased cardiovascular and cancer risk versus TNF inhibitors, leading to boxed warning update.

Generic Name

tofacitinib

Brand Names

Xeljanz, Xeljanz XR

Therapeutic Class

JAK Inhibitor

Manufacturer

Pfizer

What Pharma Signal Tracks for Xeljanz

Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Xeljanz, including serious outcomes, hospitalizations, and deaths.
FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Xeljanz products.
Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Xeljanz Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Xeljanz.

curl "https://api.pharma-signal.com/drug/safety/xeljanz" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Try the API API Reference

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Xeljanz against other JAK Inhibitor drugs, or explore the full manufacturer portfolio for Pfizer.

Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
Therapeutic class benchmarking — See how Xeljanz ranks within JAK Inhibitor on serious event rates.
Company portfolio risk — View all drugs from Pfizer with aggregate risk exposure.
AI analyst briefs — Get a natural-language safety assessment combining all data sources.